← All patents

US20160264655A1

Treating cancers with drugs targeting CREB3L1

University of Texas System

Abstract

CREB3L1 is a biomarker for identifying cancer cells sensitive to doxorubicin (daunomycin). The biomarker is used in diagnostics and screening; for example, to indicate suitability of doxorubicin chemotherapy and for pharmacological screens for agents that act through the same pathway

University
University of Texas System
Assignee
Board Of Regents, The University Of Texas System
Inventor
Jin Ye
Priority date
November 22, 2013
Filing date
May 23, 2016
Publication date
September 15, 2016
Language
en
Metadata fetched
August 29, 2026 00:24